What Verdica's 799 score means for AMPHASTAR PHARM
AMPHASTAR PHARM's composite score of 799 out of 850 places the entity in the "strong" band (740–799), indicating reliable regulatory standing across the dimensions Verdica measures. This score reflects data aggregated from state board of pharmacy records, FDA oversight, and DEA compliance tracking—the three primary regulatory bodies that govern pharmaceutical manufacturers and distributors in the United States.
A score in this range suggests that AMPHASTAR PHARM has demonstrated consistent adherence to licensing requirements and quality standards, with no major red flags in the underlying compliance data. Readers should interpret this as a provider that meets or exceeds baseline regulatory expectations in most areas, though the score also indicates room for improvement in at least one measured dimension. This is a meaningful distinction from the "excellent" band (800–850), which represents the highest tier of compliance performance.
For a business owner or procurement officer evaluating pharmacy providers, a 799 score signals that the entity is low-risk from a regulatory perspective and suitable for standard supply arrangements. However, because this score falls just below the excellent threshold, it warrants a closer look at which sub-scores are driving that gap before making a final decision.
How the sub-scores break down
Product Approval (850): This sub-score is at the maximum, indicating that AMPHASTAR PHARM's product portfolio has received full FDA approval status. In the pharmacy industry, a perfect product approval score means all manufactured or distributed products meet federal drug application requirements and are legally marketed without enforcement actions tied to unapproved drugs. This is a foundational requirement and its perfect rating reflects no current issues in this category.
Manufacturer Profile (720): This sub-score falls into the acceptable range and is the lowest of the three measures. Manufacturer profile ratings typically reflect data from FDA establishment inspections, quality system compliance, and manufacturing site certifications. A score of 720 suggests AMPHASTAR PHARM operates within regulatory standards but may have areas flagged during recent inspections or may lack certain premium certifications that would elevate the score. In the pharmacy industry, this is not unusual—many compliant manufacturers carry inspection observations that don't rise to the level of warning letters but still register in regulator records.
FDA Compliance (830): This score sits in the strong range and reflects the entity's track record with federal enforcement actions, recalls, and submission adherence. An 830 rating indicates no major compliance breaks—no warning letters, consent decrees, or significant recalls indexed in the underlying data. Minor compliance matters or resolved issues may be reflected in the points below a perfect score, but the high rating demonstrates consistent regulatory cooperation.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensure records, disciplinary histories, and facility inspection results. They track pharmacy operations, pharmacist licensing, and adherence to state-specific dispensing and recordkeeping rules. The FDA monitors drug manufacturing quality, product approvals, and facility compliance through routine and for-cause inspections. Inspectors document observations ranging from minor documentation gaps to systemic failures in manufacturing controls. The DEA tracks controlled substance handling, DEA registration status, and suspicious order reporting for entities that distribute Schedule II–V drugs.
Scores move based on factors like warning letters, import alerts, recall frequency, licensing suspensions, inspection citations, and compliance trend data. A provider without these infractions will score higher; one with unresolved violations will score lower.
Bottom line
AMPHASTAR PHARM is a strong compliance performer suitable for most pharmacy supply relationships. Before committing to a partnership, verify current DEA and state pharmacy licensure status directly with regulators, and request any recent FDA inspection reports or product safety documentation relevant to your specific needs.